Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials

Biomedicine and Pharmacotherapy

Volumn 62, Issue 10, 2008, Pages 684-689

  Vieira, Nashira Campos ^a   Herrenknecht, Christine ^a   Vacus, Joel ^b   Fournet, Alain ^c   Bories, Christian ^a   Figadère, Bruno ^a   Espindola, Laila Salmen ^d   Loiseau, Philippe M ^a  

^a UNIVERSITÉ PARIS SUD   (France)

^b Société Drugabilis   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

2 Substituted quinolines; Chemical stability; Leishmaniasis

Indexed keywords

2 (2 HYDROXYPROP 2 ENYL)QUINOLINE; 2 (2 METHOXYETHENYL)QUINOLINE; 2 PROPYLQUINOLINE; ANTILEISHMANIAL AGENT; QUINOLINE DERIVATIVE; SITAMAQUINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG IDENTIFICATION; DRUG STABILITY; FEMALE; LEISHMANIA DONOVANI; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ACUTE TOXICITY TESTS; ANIMALS; DRUG RESISTANCE; DRUG STABILITY; LEISHMANIA DONOVANI; PARASITIC SENSITIVITY TESTS; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS;

EID: 56049110215     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.09.002     Document Type: Article

References (20)

1. Hotez P.J., Molyneux D.H., Fenwick A., Kumaresan J., Ehrlich Sachs S., Sachs J.D., et al. Control of neglected tropical diseases. N Engl J Med 357 (2007) 1018-1027
2. Nakayama H., Loiseau P.M., Bories C., Torres De Ortoz S., Shinini A., Serna E., et al. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniasis. Antimicrob Agents Chemother 49 (2005) 4950-4956
3. WHO. Control of Leishmaniasis. Sixtieth World Health Assembly. Provisional agenda item 12.3, A60/10. 22 march 2007.
4. Singh R.K., Pandey H.P., and Sundar S. Visceral leishmaniasis (kala-azar): challenges ahead. Indian J Med Res 123 (2006) 331-344
5. Luque-Ortega J.R., and Rivas L. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes. Antimicrob Agents Chemother 51 (2007) 1327-1332
6. Jha T.K., Sundar S., Thakur C.P., Felton J.M., Sabin A.J., and Horton J. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 73 (2005) 1005-1011
7. Sinha PK, Jha TK, Sundar S, Dixon SA, Kellam LM, Buckley R, et al. A phase II study to evaluate the efficacy, safety tolerability and PK of oral sitamaquine vs amphotericin B in the treatment of visceral leishmaniasis caused by L. donovani in India-day 90 interim results. In: Proceedings of the 56th annual meeting of the American society of tropical medicine and hygiene. Philadelphia: 2007.
8. Wasunna M.K., Rashid J.R., Mbui J., Kirigi G., Kinoti D., Lodenyo H., et al. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg 73 (2005) 871-876
9. Fournet A., Barrios A.A., Muñoz V., Hocquemiller R., Cavé A., and Bruneton J. 2-Substituted quinoline alkaloids as potential antileishmanial drugs. Antimicrob Agents Chemother 37 (1993) 859-863
10. Fournet A., Ferreira M.E., Rojas De Arias A., Torres De Ortiz S., Fuentes S., Nakayama H., et al. In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrob Agents Chemother 40 (1996) 2447-2451
11. Nakayama H., Ferreira M.E., Rojas de Arias A., Vera de Bilbao N., Torres S., Schinini A., et al. Experimental treatment of chronic Trypanosoma cruzi infection in mice with 2-n-propylquinoline. Phytother Res 15 (2001) 630-632
12. Fakhfakh M.A., Fournet A., Prina E., Mouscadet J.F., Franck X., Hocquemiller R., et al. Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral coinfections. Bioorg Med Chem 11 (2003) 5013-5023
13. Mekouar K., Mouscadet J.F., Desmaële D., Subra F., Leh H., Savouré D., et al. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J Med Chem 41 (1998) 2846-2857
14. Bonnenfant S., Thomas C.M., Vita C., Subra F., Deprez E., Zouhiri F., et al. Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents. J Virol 78 (2004) 5728-5736
15. Gantier J.C., Fournet A., Munos M.H., and Hocquemiller R. The effect of some 2-substituted quinolines isolated from Galipea longiflora on Plasmodium vinckei petteri infected mice. Planta Med 62 (1996) 285-286
16. Martínez-Grueiro M., Giménez-Pardo C., Gómez-Barrio A., Franck X., Fournet A., Hocquemiller R., et al. Nematocidal and trichomonacidal activities of 2-substituted quinolines. Farmaco 60 (2005) 219-224
17. Bories C., Cojean S., Huteau F., and Loiseau P.M. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani. Biomed Pharmacother 62 (2008) 164-167
18. Desrivot J., Edlund P.O., Svensson R., Baranczewski P., Fournet A., Figadère B., et al. Metabolism of 2-substituted quinolines with antileishmanial activity studied in vitro with liver microsomes, hepatocytes and recombinantly expressed enzymes analyzed by LC/MS. Toxicology 235 (2007) 27-38
19. 2+, pentamidine and WR-6026 on mitochondrial membrane potential in situ. Biochem J 284 (1992) 463-467
20. Duenas-Romero A.M., Loiseau P.M., and Saint-Pierre-Chazalet M. Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes. Biochim Biophys Acta 1768 (2007) 246-252